Clinical Trial

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2023 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-03-05; most recent amendment 2023-02-16.
Status change: Not Yet Recruiting → Recruiting 2022-08-03
Trial Details
NCT Number NCT05280509
Lead Sponsor Telios Pharma, Inc.
Conditions Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Enrollment 70 participants
Start Date 2022-06-09
Primary Completion 2025-10 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2023-02-21